---
title: "INT'L GROUP plans to participate in the auction for 100% equity of Huatuo Pharmaceutical to enhance market share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/241998596.md"
description: "INT'L GROUP announced that its wholly-owned subsidiary, Zhejiang INT'L Pharmaceutical Co., Ltd., intends to participate in the auction for 100% equity of Huadong Pharmaceutical through the Zhejiang Property Exchange, with a listing reserve price of 369 million yuan. This move aims to enhance the company's market share and industry concentration in Zhejiang Province, strengthen its bargaining power with upstream suppliers, and promote the company's high-quality development"
datetime: "2025-05-27T11:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/241998596.md)
  - [en](https://longbridge.com/en/news/241998596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/241998596.md)
---

# INT'L GROUP plans to participate in the auction for 100% equity of Huatuo Pharmaceutical to enhance market share

According to the announcement from INT'L GROUP (000411.SZ), in order to further deepen the company's business layout in Zhejiang Province and enhance market share and industry concentration, the wholly-owned subsidiary Zhejiang INT'L Pharmaceutical Co., Ltd. ("INT'L Pharmaceutical") plans to participate in the auction for 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Huadong Pharmaceutical" or "transaction target") through the designated platform of Zhejiang Property Exchange, with a listing base price of 369 million yuan. The actual transfer price will be based on the final auction transfer price from Zhejiang Property Exchange.

The wholesale business of the transaction target Huadong Pharmaceutical has significant advantages in the grassroots public medical market, while its retail segment, Huadong Chain, is among the top 100 pharmaceutical retail enterprises, forming a high synergy with INT'L GROUP's existing business.

This transaction aligns with the company's strategic planning and business development needs, helping to enhance the company's market share in pharmaceutical wholesale and retail in the Zhejiang market, strengthen bargaining power with upstream suppliers, and increase influence over end consumers, thereby promoting the company's high-quality development

### Related Stocks

- [000411.CN](https://longbridge.com/en/quote/000411.CN.md)

## Related News & Research

- [Fed Meeting Prediction Market Preview: What Will Kevin Warsh Say?](https://longbridge.com/en/news/294217702.md)
- [Thune warns there aren't 50 votes to advance budget resolution after Trump demands action](https://longbridge.com/en/news/294230907.md)
- [09:01 ETTAO Clean Turns Its Award-Winning Toothbrush Into a Design Statement With the Launch of the Studio Series](https://longbridge.com/en/news/294371195.md)
- [Wesizwe Platinum suspends Bakubung mine operations after union-led employee gatherings raise safety risks](https://longbridge.com/en/news/294524307.md)
- [08:15 ETHPO.TECH Hyperbaric Chambers Support Aurelius' Accelerated Protocol for Veterans and Special Operations Forces with chronic TBI and PTSD](https://longbridge.com/en/news/294363840.md)